Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Bioaffinity Technologies Inc's Business Segments
Bioaffinity Technologies Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
8
Largest Segment
Laboratory Services
Total Revenue
$ 2
Regions Reported
-
Revenue Share by Reportable Segment - FY
- Laboratory Services0%
- Health Care Patient Service31.4%
- Histology Service Fees16.4%
- Medical Director Fees1.2%
- Department of Defense Observational Studies0.1%
- Diagnostic Research and Development0.1%
- Other Revenues0.1%
- General Corporate Activities0%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Laboratory Services | $ 3 | - |
| Health Care Patient Service | $ 0 | 31.4% |
| Histology Service Fees | $ 0 | 16.4% |
5 more segments available
Sign in to unlock the full Bioaffinity Technologies Inc dataset.
Revenue by Product & Service Category - FY
- Laboratory Services0%
- Health Care Patient Service82.4%
- Histology Service Fees16.4%
- Medical Director Fees1.2%
- Other Revenues0.1%
- Department of Defense Observational Studies0%
- Diagnostic Research and Development0%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Laboratory Services | $ 2 | - |
| Health Care Patient Service | $ 1 | 82.4% |
| Histology Service Fees | $ 0 | 16.4% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
4 more categories available
Sign in to unlock the full Bioaffinity Technologies Inc dataset.
Annual Results
Revenue Share by Reportable Segment - FY
- Laboratory Services0%
- Health Care Patient Service31.4%
- Histology Service Fees16.4%
- Medical Director Fees1.2%
- Department of Defense Observational Studies0.1%
- Diagnostic Research and Development0.1%
- Other Revenues0.1%
- General Corporate Activities0%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Laboratory Services | $ 3 | - |
| Health Care Patient Service | $ 0 | 31.4% |
| Histology Service Fees | $ 0 | 16.4% |
5 more segments available
Sign in to unlock the full Bioaffinity Technologies Inc dataset.
Description of Bioaffinity Technologies Inc
Bioaffinity Technologies Inc. is a biotechnology company dedicated to developing and commercializing innovative diagnostic tests for the early detection and monitoring of various types of cancer. The company is focused on using bioaffinity assays, which are highly sensitive and specific, to detect biomarkers associated with early-stage cancer.
One of the key technologies developed by Bioaffinity Technologies is the CyPath® Lung Test, a non-invasive blood test that can detect early-stage lung cancer. This test is based on the principle of bioaffinity, where specific proteins present in the blood bind to cancer-related antigens, allowing for the detection of tumors before they become symptomatic. The CyPath® Lung Test has shown promising results in clinical studies, with high sensitivity and specificity in detecting lung cancer at its earliest stages.
Apart from lung cancer, Bioaffinity Technologies is also working on developing diagnostic tests for other types of cancer, including breast, ovarian, and pancreatic cancer. The company's goal is to provide healthcare professionals with accurate and reliable tools for early cancer detection, leading to improved patient outcomes and survival rates.
In addition to its diagnostic tests, Bioaffinity Technologies is also involved in the development of therapeutic agents for the treatment of certain cancers. The company's research and development efforts focus on identifying novel drug targets and designing targeted therapeutics that can effectively inhibit tumor growth and progression.
Bioaffinity Technologies prides itself on its research capabilities and collaborations with leading academic institutions and cancer centers. The company has a team of experienced scientists and researchers who are dedicated to advancing the field of cancer diagnosis and treatment. They actively seek partnerships and collaborations to leverage their expertise and bring innovative solutions to the market.
Bioaffinity Technologies is committed to commercializing its technology and making it accessible to patients worldwide. The company is involved in regulatory processes to obtain necessary approvals from health authorities and plans to launch its diagnostic tests in multiple markets.
Overall, Bioaffinity Technologies Inc. is a biotechnology company at the forefront of cancer diagnostics and therapeutics. With its innovative bioaffinity assays and commitment to early cancer detection, the company aims to make a significant impact in improving patient outcomes and reducing the burden of cancer globally.
One of the key technologies developed by Bioaffinity Technologies is the CyPath® Lung Test, a non-invasive blood test that can detect early-stage lung cancer. This test is based on the principle of bioaffinity, where specific proteins present in the blood bind to cancer-related antigens, allowing for the detection of tumors before they become symptomatic. The CyPath® Lung Test has shown promising results in clinical studies, with high sensitivity and specificity in detecting lung cancer at its earliest stages.
Apart from lung cancer, Bioaffinity Technologies is also working on developing diagnostic tests for other types of cancer, including breast, ovarian, and pancreatic cancer. The company's goal is to provide healthcare professionals with accurate and reliable tools for early cancer detection, leading to improved patient outcomes and survival rates.
In addition to its diagnostic tests, Bioaffinity Technologies is also involved in the development of therapeutic agents for the treatment of certain cancers. The company's research and development efforts focus on identifying novel drug targets and designing targeted therapeutics that can effectively inhibit tumor growth and progression.
Bioaffinity Technologies prides itself on its research capabilities and collaborations with leading academic institutions and cancer centers. The company has a team of experienced scientists and researchers who are dedicated to advancing the field of cancer diagnosis and treatment. They actively seek partnerships and collaborations to leverage their expertise and bring innovative solutions to the market.
Bioaffinity Technologies is committed to commercializing its technology and making it accessible to patients worldwide. The company is involved in regulatory processes to obtain necessary approvals from health authorities and plans to launch its diagnostic tests in multiple markets.
Overall, Bioaffinity Technologies Inc. is a biotechnology company at the forefront of cancer diagnostics and therapeutics. With its innovative bioaffinity assays and commitment to early cancer detection, the company aims to make a significant impact in improving patient outcomes and reducing the burden of cancer globally.
Bioaffinity Technologies Inc. is a biotechnology company that focuses on the development of innovative diagnostic and therapeutic solutions, particularly in the field of cancer. The company has made strides in advancing its technology and offers a range of products and services targeting specific health needs. Here’s an extensive overview of the segments, products, and services offered by Bioaffinity Technologies:
1. Diagnostic Products
Bioaffinity Technologies specializes in creating diagnostic tools aimed at the early detection and monitoring of cancer.
- Diagnostic Tests: The company develops proprietary tests designed to detect cancer at earlier stages through the analysis of biomarkers. These tests may focus on various types of cancer, such as lung cancer, through methods that detect specific proteins or genetic material associated with tumors.
- Liquid Biopsy Technologies: This innovative approach allows for the detection of circulating tumor cells (CTCs) or cell-free DNA in blood samples. Liquid biopsies offer a non-invasive method for cancer detection and can be used to monitor the progression of the disease or the effectiveness of treatments.
- Biomarker Research: The company is engaged in research to identify new biomarkers that are indicative of various cancers. This research not only aids in developing diagnostic tests but also contributes to personalized medicine initiatives.
Therapeutic Solutions
In addition to diagnostics, Bioaffinity Technologies is involved in developing therapeutic solutions that leverage their unique technology platforms.
- Targeted Therapies: The company may focus on creating treatments that specifically target cancer cells while minimizing impact on healthy cells. These therapies could utilize various mechanisms such as monoclonal antibodies or small molecule drugs.
- Immunotherapy: Bioaffinity is likely to explore avenues in immunotherapy, harnessing the bodys immune system to fight cancer more effectively. This may involve the development of vaccines or adoptive cell transfer therapies.
Research and Development Services
Bioaffinity Technologies may offer research and development services to other biotech and pharmaceutical companies. This service segment can include:
- Collaborative Research Programs: Partnering with other organizations to advance research in cancer diagnostics and therapies, utilizing Bioaffinitys technological expertise and understanding of biomarkers.
- Preclinical Development Services: Assisting other companies with the preclinical development of their products, including providing access to cutting-edge technologies for testing efficacy and safety.
Regulatory Support Services
Navigating the regulatory landscape is crucial in the biotech sector, and Bioaffinity Technologies may provide consultancy or support in this area.
- Regulatory Compliance: Offering support in meeting the regulatory requirements set out by bodies like the FDA, which includes guidance on clinical trial design and submission of data for approval of new diagnostic or therapeutic products.
- Clinical Trial Management: Assisting in the design and execution of clinical trials for new diagnostic tests and therapies, ensuring adherence to relevant regulations and protocols.
Educational and Training Programs
As part of its commitment to advancing healthcare, Bioaffinity may offer educational resources and training programs.
- Workshops and Seminars: Conducting educational sessions focused on emerging cancer diagnostics and treatment methodologies, aimed at healthcare professionals, researchers, and students.
- Publication and Resources: Producing literature and brown papers that outline the latest technologies in cancer diagnostics and therapeutics, contributing to the body of knowledge in the field.
Conclusion
Bioaffinity Technologies Inc. has a multifaceted approach focusing on cancer diagnostics and therapeutics. Through the development of innovative diagnostic products, targeted therapies, and extensive research and development efforts, the company aims to make significant contributions to cancer care while advancing the life sciences industry. The integration of education and regulatory support services further underscores Bioaffinitys commitment to improving healthcare outcomes through innovation and collaboration.
1. Diagnostic Products
Bioaffinity Technologies specializes in creating diagnostic tools aimed at the early detection and monitoring of cancer.
- Diagnostic Tests: The company develops proprietary tests designed to detect cancer at earlier stages through the analysis of biomarkers. These tests may focus on various types of cancer, such as lung cancer, through methods that detect specific proteins or genetic material associated with tumors.
- Liquid Biopsy Technologies: This innovative approach allows for the detection of circulating tumor cells (CTCs) or cell-free DNA in blood samples. Liquid biopsies offer a non-invasive method for cancer detection and can be used to monitor the progression of the disease or the effectiveness of treatments.
- Biomarker Research: The company is engaged in research to identify new biomarkers that are indicative of various cancers. This research not only aids in developing diagnostic tests but also contributes to personalized medicine initiatives.
Therapeutic Solutions
In addition to diagnostics, Bioaffinity Technologies is involved in developing therapeutic solutions that leverage their unique technology platforms.
- Targeted Therapies: The company may focus on creating treatments that specifically target cancer cells while minimizing impact on healthy cells. These therapies could utilize various mechanisms such as monoclonal antibodies or small molecule drugs.
- Immunotherapy: Bioaffinity is likely to explore avenues in immunotherapy, harnessing the bodys immune system to fight cancer more effectively. This may involve the development of vaccines or adoptive cell transfer therapies.
Research and Development Services
Bioaffinity Technologies may offer research and development services to other biotech and pharmaceutical companies. This service segment can include:
- Collaborative Research Programs: Partnering with other organizations to advance research in cancer diagnostics and therapies, utilizing Bioaffinitys technological expertise and understanding of biomarkers.
- Preclinical Development Services: Assisting other companies with the preclinical development of their products, including providing access to cutting-edge technologies for testing efficacy and safety.
Regulatory Support Services
Navigating the regulatory landscape is crucial in the biotech sector, and Bioaffinity Technologies may provide consultancy or support in this area.
- Regulatory Compliance: Offering support in meeting the regulatory requirements set out by bodies like the FDA, which includes guidance on clinical trial design and submission of data for approval of new diagnostic or therapeutic products.
- Clinical Trial Management: Assisting in the design and execution of clinical trials for new diagnostic tests and therapies, ensuring adherence to relevant regulations and protocols.
Educational and Training Programs
As part of its commitment to advancing healthcare, Bioaffinity may offer educational resources and training programs.
- Workshops and Seminars: Conducting educational sessions focused on emerging cancer diagnostics and treatment methodologies, aimed at healthcare professionals, researchers, and students.
- Publication and Resources: Producing literature and brown papers that outline the latest technologies in cancer diagnostics and therapeutics, contributing to the body of knowledge in the field.
Conclusion
Bioaffinity Technologies Inc. has a multifaceted approach focusing on cancer diagnostics and therapeutics. Through the development of innovative diagnostic products, targeted therapies, and extensive research and development efforts, the company aims to make significant contributions to cancer care while advancing the life sciences industry. The integration of education and regulatory support services further underscores Bioaffinitys commitment to improving healthcare outcomes through innovation and collaboration.